Century Therapeutics Inc (IPSC) fair value: what the stock is really worth
As of Nov 11, 2026: fair value (intrinsic value) of Century Therapeutics Inc stock $0.35, price $1.74, that is 80.0% below the price, quality 48 out of 100. Rating: strongly overvalued. Calculated from audited financials with 2 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 11, 2026.
How to read this chart
60‑month range $0.3891 – $31.93 · fair‑value band $0.3145 – $0.3995 · the $1.74 price screens above the $0.3485 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 11, 2026.
Follow Century Therapeutics in your weekly email
Every Wednesday you see whether Century Therapeutics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases.
Show moreShow less
Its lead product candidate is CNTY-813, an iPSC-derived beta islet cell replacement therapy engineered with Allo-Evasion 5.0 for the treatment of type 1 diabetes.
The company is also involved in the development of CNTY-308, a CD19-targeted CD4+/CD8+ CAR-iT cell therapy engineered with Allo-Evasion 5.0 as a potential treatment for B-cell-mediated autoimmune diseases; and CNTY-101, an allogeneic, iPSC-derived CAR-iNK cell therapy with six precision gene edits engineered to express CD19 CAR, with Allo-Evasion 1.0 edits designed for the treatment of CD19 for B-cell mediated autoimmune diseases.
Century Therapeutics, Inc. was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.
Stock analysis
Century Therapeutics Inc (IPSC) currently trades at $1.74, while our model-based Fair Value estimate is $0.3485, 80% below the price, so the stock looks overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 2 models at a data quality of 96/100, which puts the data coverage at low.
Scenario range: $0.3145 (bear) to $0.3995 (bull), the price of $1.74 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 48/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Century Therapeutics Inc reported revenue of $109M in FY2025 versus $1.1M in FY2021, a compound +218.7%/yr. Reported net income was −$9.6M in FY2025.
Key figures
Market cap $358M Small · EPS (TTM) $−0.9000 · Net margin −8.8% · Return on equity −49.7% · Return on assets (EBIT) −27.1% (5-year average) · Free cash flow −$105M · Net cash $18.3M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 6 out of 100 (low confidence).
What moves the price
The share trades about 41% below its 52-week high and 275% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −80%, IPSC screens richer than that median.
Fair Value models
Bear$0.3145Fair Value $0.3485Bull$0.3995
Price $1.74 · Downside -80.0%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
Owner Earnings$0.3700$0.4100$0.470076
NCAV (Graham)$0.2000$0.3100$0.390054
All 2 models by family
DCF Models
Owner Earnings$0.3700$0.4100$0.470076
Asset-Based
NCAV (Graham)$0.2000$0.3100$0.390054
The fair value above starts from this blend and is adjusted for dilution from new shares.
In the last 6 months, 2 officers or directors sold shares worth $21,839 and none bought.
SaleDouglas CarrSVP Finance & Operations11× since Dec 8, 2025: 12,490 shares, avg. $2.31$28,812Nov 3, 2026
SaleGregory RussottiOfficer7× since Dec 8, 2025: 17,310 shares, avg. $2.32$40,145Sep 14, 2026
BuyChad CowanChief Scientific Officer58,060 shares at $0.8500$49,351Dec 22, 2025
BuyBrent PfeiffenbergerPresident and CEO, Director2× since Nov 19, 2025: 87,000 shares, avg. $0.5478$47,660Dec 12, 2025
SaleChad CowanChief Scientific Officer5,462 shares at $0.5000$2,731Nov 20, 2025
SaleBrent PfeiffenbergerPresident and CEO, Director32,456 shares at $0.4500$14,605Nov 17, 2025
Plus 7 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.33/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+1,556.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+175.9%
Revenue growth 10 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−19.5%
’15
’16
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−8,968.1% (2021) → −13.8% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Compare Century Therapeutics Inc with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 849 stocks
Beats the industry median on 5/7 measures
Overall it ranks above its industry peers.
Valuation
Quality Score48 · Above median
Fair Value upside−80.0% · Bottom 25%
Profitability
Return on assets−4.3% · Above median
Net margin (12 months)−8.8% · Below median
Operating margin (12 months)0.0% · Above median
Balance sheet
Debt / equity0.02× · Below median
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/B2.25× · Cheaper than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)0· sector 0
PAST (return on equity)0· sector 0
HEALTH (low debt)99· sector 96
DIVIDEND (yield)0· sector 20
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Century Therapeutics Inc (IPSC) overvalued or undervalued?
As of Nov 11, 2026, our model estimates a fair value of $0.3485 versus a price of $1.74, about 80% lower (overvalued).
What is the fair value of IPSC?
Our model-based fair value for Century Therapeutics Inc is $0.3485 (as of Nov 11, 2026), built from audited fundamentals. The current price: $1.74.
What is the quality score of IPSC?
Century Therapeutics Inc has a Quality Score of 48/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Century Therapeutics Inc (IPSC)?
Our model-based price target is the fair value of $0.3485 (as of Nov 11, 2026) from 2 valuation models. Cautious scenario $0.3145, optimistic scenario $0.3995. It is a calculation from audited fundamentals, not an analyst target.
What is the Century Therapeutics Inc stock forecast for 2026?
Our models put fair value at $0.3485, about 80% lower versus a price of $1.74 (overvalued). Cautious scenario $0.3145, optimistic scenario $0.3995. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Century Therapeutics Inc (IPSC)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Century Therapeutics Inc it is $0.3485 per share (as of Nov 11, 2026), against a price of $1.74. It is the blended result of 2 valuation models in 2 families (DCF Models, Asset-Based).
Is Century Therapeutics Inc stock overvalued or undervalued in 2026?
As of Nov 11, 2026, IPSC trades above its calculated fair value: price $1.74, fair value $0.3485, a gap of about −80% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of IPSC?
No. The price is what the market pays today ($1.74); the fair value is what the company's own numbers justify ($0.3485). For Century Therapeutics Inc the two are $1.39 per share apart. That gap is exactly why we show both numbers side by side.
How much is Century Therapeutics Inc worth?
The market values Century Therapeutics Inc at about $358M (market capitalisation, as of Nov 11, 2026). Per share that is $1.74; our models calculate a fair value of $0.3485 per share.
What do the bullish and bearish scenarios say about IPSC?
Our models span a range for Century Therapeutics Inc: cautious scenario $0.3145, base $0.3485, optimistic $0.3995 per share (as of Nov 11, 2026, price $1.74). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Century Therapeutics Inc (IPSC)?
Balance-sheet figures for Century Therapeutics Inc (as of Nov 11, 2026): return on equity −49.7%, debt of 0.02 per unit of equity. They feed the Quality Score of 48/100, which measures business quality independently of the share price.
How far is IPSC from its 52-week high?
Century Therapeutics Inc trades at $1.74, about 41% below its 52-week high of $2.94 and 275% above the low of $0.4645 (as of Nov 11, 2026). Distance from the high says nothing about value: that is what the fair value of $0.3485 is for.
Which stocks are comparable to Century Therapeutics Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Century Therapeutics Inc stock attractive at the current price?
The data as of Nov 11, 2026: price $1.74, calculated fair value $0.3485 (−80%), Quality Score 48/100, from 2 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of IPSC calculated?
We run Century Therapeutics Inc through 2 models from 2 families: DCF Models, Asset-Based. Every model gets the same audited fundamentals; the fair value of $0.3485 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0% above its aggregate fair value. Century Therapeutics Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Century Therapeutics Inc (IPSC)?
The closing price on Nov 11, 2026 was $1.74. Our model-based fair value is $0.3485, about 80% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Century Therapeutics Inc right now?
The price sits above even our optimistic bull case ($0.3995). The favourable scenario is already priced in. Weak quality (48/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Key figures of Century Therapeutics Inc
How large is the market capitalisation of Century Therapeutics Inc (IPSC)?
The market capitalisation of Century Therapeutics Inc is $358M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Century Therapeutics Inc (IPSC)?
Earnings per share at Century Therapeutics Inc are $−0.9000. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Century Therapeutics Inc (IPSC)?
The net margin of Century Therapeutics Inc is −8.8% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Century Therapeutics Inc (IPSC)?
The return on equity (ROE) of Century Therapeutics Inc is −49.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Century Therapeutics Inc (IPSC)?
On an EBIT basis the return on assets of Century Therapeutics Inc is −27.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much free cash flow does Century Therapeutics Inc (IPSC) generate?
The free cash flow of Century Therapeutics Inc is −$105M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Century Therapeutics Inc (IPSC) hold?
Century Therapeutics Inc holds more cash than debt, $18.3M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Century Therapeutics Inc in the live analysis
One click puts Century Therapeutics Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 11, 2026
